3410 Central Expressway
United States - Map
XenoPort, Inc., a biopharmaceutical company, focuses on developing and commercializing a portfolio of internally discovered product candidates for the treatment of neurological disorders. The company markets Gabapentin Enacarbil extended-release tablets for the treatment of moderate-to-severe primary restless legs syndrome and for the management of postherpetic neuralgia in adults under the Regnite name in Japan and five other Asian countries. The companys lead product candidate is Arbaclofen Placarbil, a transported prodrug of R-baclofen that is in Phase III clinical trial for the potential treatment of spasticity in patients with multiple sclerosis (MS), stroke and cerebral palsy, and spinal cord injury. Its product candidates in clinical development also include XP21279, a transported prodrug of Levodopa, which has completed Phase II clinical trial for the treatment of Parkinsons disease; and XP23829, a prodrug of monomethyl fumarate that is in Phase I clinical trial for the potential treatment of relapsing-remitting MS, psoriasis, and/or other disorders. The company has strategic alliance with Astellas Pharma Inc. to develop and commercialize Gabapentin Enacarbil under the Regnite name in Japan, Korea, the Philippines, Indonesia, Thailand, and Taiwan. XenoPort, Inc. was founded in 1999 and is based in Santa Clara, California.
|Xenoport, Inc.’s ISS Governance QuickScore as of May 1, 2013 is 8. The pillar scores are Audit: 1; Board: 2; Shareholder Rights: 9; Compensation: 9.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Dr. Ronald W. Barrett Ph.D.,
Co-Founder, Chief Exec. Officer and Director
|Mr. William G. Harris ,
Chief Financial Officer, Principal Accounting Officer and Sr. VP of Fin.
|Mr. Vincent J. Angotti ,
Chief Operating Officer and Exec. VP
|Ms. Gianna M. Bosko ,
Chief Admin. Officer, Sr. VP, Gen. Counsel and Sec.
|Mr. Gregory T. Bates D.V.M.,
Sr. VP of Regulatory Affairs and Quality
|Amounts are as of Dec 30, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|